New Evidence Available

Updated Recommendation

A new evidence synthesis was published:2022, Therapeutics and COVID-19: living guideline, 3 March 2022.

View latest version (2022)

Bibliographic information

GuidelineTherapeutics and COVID-19: living guideline, 14 January 2022.
Year of Publication2022
Issuing InstitutionWorld Health Organization

Recommendation

Retired

Therapeutics and COVID-19. The World Health Organization (WHO) suggests against administering remdesivir in addition to usual care

Recommended against

Conditional

Notes and Remarks

Practical Info The GDG made a conditional recommendation against using remdesivir for treatment of hospitalized patients with COVID-19. If administration of remdesivir is considered, it should be noted that its use is contraindicated in those with liver (ALT > 5 times normal at baseline) or renal (eGFR < 30 mL/minute) dysfunction. To date, it can only be administered intravenously, and it has relatively limited availability.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

Therapeutics and COVID-19: living guideline, 17 December 2020.

Year2020
InstitutionWorld Health Organization
Guideline

Therapeutics and COVID-19: living guideline, 31 March 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Therapeutics and COVID-19: living guideline, 6 July 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Therapeutics and COVID-19: living guideline, 24 September 2021.

Year2021
InstitutionWorld Health Organization
Guideline

Therapeutics and COVID-19. Living guideline. 7 December 2021

Year2021
InstitutionWorld Health Organization